Assessing efficacy and tolerability of a modified lenalidomide/bortezomib/dexamethasone (VRd-28) regimen using weekly bortezomib in multiple myeloma

Publication/Presentation Date

10-2019

Volume

19

Issue

10

First Page

217

Last Page

218

Disciplines

Medicine and Health Sciences

Department(s)

Fellows and Residents

Document Type

Article

Share

COinS